WebDoctor Encyclopedia

Childhood Genitourinary

Renal medullary carcinoma (RMC)

Renal medullary carcinoma is a rare, aggressive kidney cancer of teenagers and young adults with sickle cell trait or related conditions. It is defined by SMARCB1 loss, often causes blood in the urine, and is treated with platinum chemotherapy, surgery and clinical trials.

Medically reviewed Last reviewed October 19, 2026

What is renal medullary carcinoma?

Renal medullary carcinoma (RMC) is a rare and aggressive kidney cancer that mainly affects teenagers and young adults who have sickle cell trait or, less often, another sickle haemoglobin condition such as haemoglobin SC disease.

It starts in the medulla, the inner part of the kidney, near the area where urine collects before draining to the bladder.

RMC was first described in 1995 as the “seventh sickle cell nephropathy”, the seventh kidney problem known to be linked with sickle haemoglobin (Davis et al., 1995). Almost all affected people are of African, Mediterranean, Middle Eastern or South Asian ancestry, the groups in which sickle cell trait is most common.

Every RMC has lost the function of a tumour suppressor gene called SMARCB1 (also known as INI1). For this reason, the World Health Organization (WHO) now calls it SMARCB1-deficient renal medullary carcinoma (Calderaro et al., 2012).

RMC tends to grow and spread quickly, and most people already have spread to other organs when they are diagnosed. It does not respond well to many drugs that work in other kidney cancers. Treatment usually involves platinum-based chemotherapy, and surgery when the cancer is localised. Research into new treatments is very active (Msaouel et al., 2019).

1. Key facts at a glance

Feature Details
Type of cancer Aggressive carcinoma of the kidney medulla
How common Very rare; well under 1% of kidney cancers
Typical age Teens to 30s; median late 20s
Sex About twice as common in males
Key link Sickle cell trait or other sickle haemoglobin disorders
Hallmark Loss of SMARCB1 (INI1)
Side More often the right kidney
Main treatments Platinum-based chemotherapy; nephrectomy for localised disease; clinical trials
Outlook Serious; most people have spread at diagnosis

2. Causes and risk factors

Sickle cell trait

People with sickle cell trait carry one copy of the sickle haemoglobin gene (HbAS). Most never have health problems. However, the inner part of the kidney, the medulla, has low oxygen levels, high salt concentration and slow blood flow. In these conditions, red blood cells with sickle haemoglobin can change shape and block small vessels.

Researchers think that repeated low oxygen and injury in the medulla may encourage cells to lose SMARCB1, leading to cancer (Msaouel et al., 2020).

Factor Notes
Sickle cell trait (HbAS) Present in most people with RMC
Haemoglobin SC disease Also linked
Sickle cell disease (HbSS) Reported rarely
Young age Most are 10-40 years old
Male sex About twice as common
Strenuous physical activity Suggested as a possible contributor, because it lowers oxygen in the kidney; not proven

Sickle haemoglobin conditions explained

Condition Genes Usual health effects
Sickle cell trait (HbAS) One sickle gene, one normal gene Usually none; sometimes blood in the urine; small risk of RMC
Haemoglobin SC disease (HbSC) One sickle gene, one haemoglobin C gene A milder form of sickle cell disease
Sickle cell anaemia (HbSS) Two sickle genes Pain crises, anaemia, organ damage

Sickle cell trait is common. It is carried by about 1 in 13 Black Americans and by many people in sub-Saharan Africa, the Mediterranean, the Middle East and India. RMC is very rare, so almost everyone with sickle cell trait will never develop it.

The SMARCB1 gene

SMARCB1 is part of a complex that controls how tightly DNA is packed and which genes are switched on. When it is lost, growth-promoting genes such as MYC become overactive. The same gene is lost in malignant rhabdoid tumours of children.

In RMC, SMARCB1 is usually lost through breaks and rearrangements of chromosome 22, rather than inherited mutations. RMC is not inherited, although the sickle cell trait that predisposes to it is.

Without sickle cell trait

Rarely, a tumour with the same features occurs in someone without a sickle haemoglobin disorder. This is called renal cell carcinoma, unclassified with medullary phenotype.

3. How does it look

On scans

Feature Typical appearance
Location Centre of the kidney (medulla), often the right kidney
Growth pattern Infiltrative, spreading through the kidney without clear borders
Kidney shape Often keeps its overall bean shape despite the tumour
Contrast Patchy enhancement, less than the normal kidney
Urine-collecting system Dilatation (caliectasis) from blockage
Lymph nodes Enlarged nodes around the kidney and aorta are common
Spread Lungs, liver, bone, adrenal glands

Under the microscope

Feature Description
Pattern Sheets, glands, cords and a “reticular” or sieve-like (cribriform) pattern
Background Dense fibrous (desmoplastic) tissue with inflammation
Cells Large cells with prominent nucleoli; some look rhabdoid
Sickled red cells Often visible in blood vessels
SMARCB1 (INI1) stain Lost in tumour cells, the key test
Other stains Keratin and PAX8 positive; OCT3/4 sometimes positive

How RMC differs from other kidney cancers

Feature Renal medullary carcinoma Clear cell kidney cancer
Typical age Teens to 30s 60s and 70s
Main link Sickle haemoglobin Smoking, obesity, high blood pressure, VHL
Starts in Medulla (inner kidney) Cortex (outer kidney)
Gene change SMARCB1 loss VHL loss
Response to VEGF tablets Poor Often good
Main drug treatment Platinum chemotherapy Immunotherapy and VEGF tablets

4. Symptoms

Common symptoms

  • Blood in the urine (haematuria), the most common symptom
  • Pain in the side (flank) or back
  • Pain in the tummy
  • Weight loss without trying
  • Tiredness
  • Fever
  • A lump in the side or tummy

Symptoms of spread

Site Possible symptoms
Lungs Cough, breathlessness, chest pain
Lymph nodes Swelling in the neck or groin; back pain from nodes in the abdomen
Bones Bone pain, fracture
Liver Pain under the right ribs, jaundice
Brain Headache, seizures (rare)

When to seek medical advice

Anyone with sickle cell trait or sickle cell disease who notices blood in the urine should see a doctor promptly. Blood in the urine is very common in sickle cell trait and is usually harmless, but it should never be ignored. Doctors should arrange imaging of the kidneys, usually a CT or MRI, rather than assuming the cause is benign (Beckermann et al., 2017).

5. Diagnosis

Test Purpose
Urine test Confirms blood in the urine
Haemoglobin electrophoresis Confirms sickle cell trait or other haemoglobin disorders
CT or MRI of the abdomen Shows the tumour and lymph nodes
CT of the chest Checks for lung spread
Biopsy Confirms the diagnosis, including loss of SMARCB1
Bone scan, brain MRI or PET-CT If symptoms suggest spread
Blood tests Blood count, kidney and liver function

RMC can be confused with urothelial carcinoma (a cancer of the urine-collecting system), collecting duct carcinoma or lymphoma. A SMARCB1 stain is essential in any young person with an aggressive kidney tumour and a sickle haemoglobin disorder (Msaouel et al., 2019).

6. Treatment

Treatment should be planned at a specialist centre with experience in rare kidney cancers, ideally with access to clinical trials.

Localised disease

Treatment Notes
Radical nephrectomy Removal of the whole kidney, often with nearby lymph nodes
Chemotherapy Often considered before or after surgery because the risk of spread is high
Close follow-up Frequent scans to detect early recurrence

Advanced (metastatic) disease

Treatment Notes
Platinum-based chemotherapy The standard first treatment, such as carboplatin with paclitaxel, or cisplatin-based combinations; responses occur in about a third of people (Shah et al., 2017)
Gemcitabine with doxorubicin Sometimes used after first-line chemotherapy
Clinical trials Strongly recommended; drugs that target EZH2, proteasomes and other pathways are being studied
Surgery Removal of the kidney may be considered after a good response to chemotherapy
Radiotherapy To relieve pain or treat individual metastases

Treatments that work poorly

Drugs that work well in common kidney cancers, such as VEGF-targeted tablets (for example sunitinib) and mTOR inhibitors, have little effect in RMC. Responses to immune checkpoint inhibitors have been reported in individual patients, but in a phase 2 trial, nivolumab with ipilimumab did not work and some cancers grew faster (Soeung et al., 2025).

Care for sickle haemoglobin disorders

People with sickle cell disease need careful management of their blood condition during cancer treatment, including hydration, infection prevention and sometimes blood transfusions. Sickle cell trait itself rarely needs treatment.

Side effects

Treatment Possible side effects
Nephrectomy Pain, bleeding, infection; reduced kidney reserve
Platinum chemotherapy Nausea, low blood counts, infections, hair loss, nerve damage, hearing changes, kidney strain
Paclitaxel Hair loss, nerve tingling, allergic reactions
Radiotherapy Tiredness, skin changes, local effects

What treatment involves day to day

Part of treatment What to expect
Chemotherapy Given through a drip, usually as a day patient, in cycles every 3 weeks
Scans CT every 2-3 cycles to check the response
Surgery Hospital stay of about 3-7 days; return to normal activities over 4-6 weeks
Fertility Sperm or egg storage should be discussed before chemotherapy

RMC in children and teenagers

RMC is among the kidney cancers seen in older children and adolescents, although it is much rarer than Wilms tumour. Young people are treated by paediatric or teenage and young adult cancer teams, often within international study groups. Treatment follows the same principles: surgery for localised disease and platinum-based chemotherapy, with a strong emphasis on clinical trials.

7. Outlook (prognosis)

Measure Approximate figures
Spread at diagnosis About 2 in 3 to 4 in 5 people
Median survival, all patients About 13 months in a multicentre study (Shah et al., 2017)
Localised disease removed by surgery Some people remain free of disease long term

The outlook is serious, but survival has improved with platinum chemotherapy and better supportive care. A growing understanding of the biology of SMARCB1 loss is leading to new trial drugs (Msaouel et al., 2020).

In the large multicentre study, nearly all people with spread at diagnosis needed chemotherapy, and those whose cancer responded to platinum treatment lived longer. People treated with surgery for localised disease had the best results, although relapse was still common (Shah et al., 2017).

Factors linked with a better outlook

  • Localised disease that can be completely removed
  • Good response to chemotherapy
  • Good general health

8. Follow-up

Follow-up Typical schedule
CT of the chest, abdomen and pelvis Every 2-3 months at first, because recurrence can be fast
Blood tests Kidney function, blood count
Kidney function checks Lifelong after nephrectomy, especially with sickle cell trait
Sickle cell care Continued haematology support for people with sickle cell disease

9. Living with renal medullary carcinoma

  • Protect your remaining kidney: stay well hydrated and avoid regular use of anti-inflammatory painkillers such as ibuprofen
  • Ask about fertility preservation before chemotherapy
  • Tell relatives that sickle cell trait runs in families, so they can be tested
  • Seek support from young adult cancer services and kidney cancer charities
  • Ask about clinical trials at the start and at each change of treatment
  • Get psychological support; a serious diagnosis at a young age is hard for patients and families

10. Frequently asked questions

Question Answer
Does sickle cell trait mean I will get kidney cancer? No. RMC is very rare, even among people with sickle cell trait
Is RMC inherited? The cancer itself is not, but sickle cell trait is
Should people with sickle cell trait be screened? Routine screening is not recommended, but blood in the urine should always be investigated
Why don’t standard kidney cancer drugs work? RMC has different biology, driven by loss of SMARCB1
Can children get RMC? Yes, rarely, usually older children and teenagers
Should I join a clinical trial? Specialists strongly recommend considering trials
Can I live with one kidney? Yes. One healthy kidney is enough for normal life, but it needs protecting
Does exercise cause RMC? This has been suggested but not proven; staying active is still encouraged

11. Questions to ask your care team

  • Has the tumour been tested for SMARCB1 (INI1) loss?
  • Has the cancer spread?
  • Which chemotherapy do you recommend, and why?
  • Is surgery an option for me now or later?
  • Are there clinical trials I could join?
  • Should my family be tested for sickle cell trait?

Resources

  1. Beckermann, K.E. et al. (2017) ‘Renal medullary carcinoma: establishing standards in practice’, Journal of Oncology Practice, 13(7), pp. 414-421.
  2. Calderaro, J. et al. (2012) ‘SMARCB1/INI1 inactivation in renal medullary carcinoma’, Histopathology, 61(3), pp. 428-435.
  3. Davis, C.J., Mostofi, F.K. and Sesterhenn, I.A. (1995) ‘Renal medullary carcinoma: the seventh sickle cell nephropathy’, American Journal of Surgical Pathology, 19(1), pp. 1-11.
  4. Msaouel, P. et al. (2019) ‘Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma’, Clinical Genitourinary Cancer, 17(1), pp. 1-6.
  5. Msaouel, P. et al. (2020) ‘Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma’, Cancer Cell, 37(5), pp. 720-734.
  6. Shah, A.Y. et al. (2017) ‘Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study’, BJU International, 120(6), pp. 782-792.
  7. Soeung, M. et al. (2025) ‘Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence’, Nature Communications, 16(1), 10474.
  8. National Cancer Institute (2026) Renal Cell Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.